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Abstract
Background Medication-induced salivary gland dysfunc-
tion (MISGD), xerostomia (sensation of oral dryness), and
subjective sialorrhea cause significant morbidity and
impair quality of life. However, no evidence-based lists of
the medications that cause these disorders exist.
Objective Our objective was to compile a list of medica-
tions affecting salivary gland function and inducing
xerostomia or subjective sialorrhea.
Data Sources Electronic databases were searched for rel-
evant articles published until June 2013. Of 3867 screened
records, 269 had an acceptable degree of relevance, quality
of methodology, and strength of evidence. We found 56
chemical substances with a higher level of evidence and 50
with a moderate level of evidence of causing the above-
mentioned disorders. At the first level of the Anatomical
Therapeutic Chemical (ATC) classification system, 9 of 14
anatomical groups were represented, mainly the alimen-
tary, cardiovascular, genitourinary, nervous, and respira-
tory systems. Management strategies include substitution
or discontinuation of medications whenever possible, oral
or systemic therapy with sialogogues, administration of
saliva substitutes, and use of electro-stimulating devices.
Limitations While xerostomia was a commonly reported
outcome, objectively measured salivary flow rate was
rarely reported. Moreover, xerostomia was mostly assessed
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as an adverse effect rather than the primary outcome of
medication use. This study may not include some medi-
cations that could cause xerostomia when administered in
conjunction with others or for which xerostomia as an
adverse reaction has not been reported in the literature or
was not detected in our search.
Conclusions We compiled a comprehensive list of medi-
cations with documented effects on salivary gland function
or symptoms that may assist practitioners in assessing
patients who complain of dry mouth while taking medi-
cations. The list may also prove useful in helping practi-
tioners anticipate adverse effects and consider alternative
medications.
Key Points
We compiled a comprehensive list of medications
with documented effects on salivary gland function
or symptoms that may assist practitioners assessing
patients who complain of dry mouth while taking
medications.
The list may also prove useful in helping
practitioners anticipate oral adverse effects and
consider alternative medications.
1 Introduction
Increased life expectancy, aging populations, and the
association of these with polypharmacy have been
intriguing topics over the last few decades. The World
Health Statistics of 2014 published on the World Health
Organization website reports a life expectancy of 55–87
years in its various constituent countries, with even the
lower economy countries reporting rapid increases in life
expectancy. However, with increased age comes a greater
number of ailments, which in turn is indicative of a higher
intake of medications.
Medications for the treatment of various diseases may
also cause adverse effects, including those related to the
oral cavity by their effects on the salivary glands. Apart
from medications used to treat salivary gland disorders,
other medications can also have the following adverse
effects: salivary gland dysfunction (SGD), including sali-
vary gland hypofunction (SGH) (an objectively measured
decrease in salivation) or objective sialorrhea (an excessive
secretion of saliva), xerostomia (subjective feeling of dry
mouth), or subjective sialorrhea (feeling of having too
much saliva). Medication-induced SGH and objective
sialorrhea are collectively termed medication-induced
salivary gland dysfunction (MISGD). The possible adverse
effects associated with these disorders, especially SGH,
include dental caries, dysgeusia, oral mucosal soreness, and
oral candidiasis.
Current literature guiding clinicians in the prescribing of
medications while considering the relevant adverse effects
on salivary glands is very scarce. Most of the available
literature attempting to list relevant drugs comprises a
compendium based on manufacturers’ drug profiles, nar-
rative reviews, and case reports, or original research papers
not containing a overall list of medications [1–10]. A
systematic evidence-based list that identifies and lists
medications that could objectively be associated with
MISGD, xerostomia, or subjective sialorrhea is lacking.
Hence, the MISGD group of the World Workshop on Oral
Medicine VI (WWOM VI) aimed to review the current
knowledge on this subject and compile a list of medications
and their objective effects on salivary gland function, based
on a high level of evidence and relevance.
2 Materials and Methods
The MISGD group comprised five reviewers (AA, RJ, NN,
YS, and AlV), six consultants (senior experts in fields
related to MISGD: DA, CD, JE, AMP, GP, and ArV), one
research librarian (RM), one group head (AW), and two
supervisors on behalf of the WWOM VI Steering Com-
mittee (SBJ and ARK). This review addresses one of the
MISGD topics covered by the group, an updated classifi-
cation of medications reported to cause objective SGD. The
research method was based on the policies and standards
set forth by a task force for WWOM IV [11] and by the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) statement [12], which was
adapted to the current review.
2.1 Step 1: Scope Definition
The current review covered seven research questions, as
follows:
Which medications have been reported to induce:
1. SGD in humans?
2. SGD in animals?
3. xerostomia but not SGD?
4. drooling but not SGD?
5. xerostomia-related oral symptoms (but not SGD) other
than excessive dryness/wetness?
6. xerostomia but have not been tested yet for induction
of SGD?
7. drooling but have not been tested yet for induction of
SGD?
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2.2 Step 2: Search Term Selection
The following keywords and subject headings were selec-
ted for each research question:
Q1. Medication/drugs/humans AND salivary gland dys-
function, xerostomia, dry mouth, reduced salivary
flow rate, hyposalivation, sialorrhea, drooling.
Q2. Medication/drugs/animals AND salivary gland dys-
function, reduced salivary flow rate, hyposalivation,
drooling.
Q3. Medication/drugs AND xerostomia, dry mouth,
hyposalivation AND NOT salivary dysfunction.
Q4. Medication/drugs AND drooling/sialorrhea/hyper-
salivation/ptyalism/increased salivary flow rate
AND NOT salivary dysfunction.
Q5. Medication/drugs AND salivary glands/saliva/xeros-
tomia/dry mouth/hyposalivation AND NOT salivary
gland dysfunction, oral sensory complaints.
Q6. Medication/drugs AND salivary glands/saliva/xeros-
tomia/dry mouth/hyposalivation AND NOT salivary
gland dysfunction/assessment.
Q7. Medication/drugs AND drooling/sialorrhea/hyper-
salivation/ptyalism AND NOT salivary gland dys-
function/assessment.
2.3 Step 3: Literature Search
Our literature search was conducted, through June 2013, in
the PubMed, Embase, and Web of Science databases based
on our chosen keywords and subject headings where
applicable and was not limited by publication date, publi-
cation type or language. In addition, group members were
encouraged to submit articles of interest located through
referral or hand searching. The search was completed by a
hand search of the reference lists in the eligible papers.
After duplicates were removed, 3867 records were retained
for Step 4.
2.4 Step 4: Record Screening for Eligibility
Each of the 3867 records was screened independently by
the reviewers, who were supervised by the consultants.
Papers were either retained for further analysis or excluded
because they lacked relevance to any of the research
questions; 269 papers relevant to the aforementioned topics
were retained.
2.5 Step 5: Paper Selection for Type of Study,
Relevance, and Level of Evidence
This step started with calibration among the reviewers to
ensure they applied similar standards in the performance of
their reviews. Papers were then divided among the
reviewers, who analyzed publication titles, abstracts, and
the materials and methods sections for key parameters.
2.6 Medication General Inclusion and Exclusion
Criteria
1. Particular drugs for which MISGD has been reported
were included.
2. A group of drugs or a combination of two or more drugs
without specifying the individual MISGD of each drug
under the group or combination were excluded.
3. Drugs reported to induce SGD or used in therapeutic
aspects of SGD were excluded. Thus, parasympath-
omimetics (e.g., pilocarpine and cevimeline) and the
anti-cholinesterases (e.g., physostigmine and neostig-
mine), which are used for stimulation of salivary flow in
patients experiencing a dry mouth, were not included.
4. Research drugs that were not yet marketed by the time
of writing this manuscript, or that were subsequently
removed from the market, were excluded.
Next, the retained articles were given scores based on the
following assessments:
(1) The degree of relevance: level A (study dedicated to
MISGD or xerostomia) or level B (study dedicated to
adverse effects of medications).
(2) The strength of methodology provided in the paper:
level 1 (typically meta-analyses, systematic reviews,
and randomized controlled trials [RCTs]), level 2
(typically open-label trials, observational studies,
animal studies, and epidemiological studies), or level
3 (typically narrative reviews and textbooks).
It should be noted that, in addition to the type of study
(RCT, review, etc.), the quality of study design and per-
formance were considered in assigning the level of evi-
dence. Hence, articles were assigned scores in order of
decreasing levels of evidence as follows: A1[B1[
A2[B2[A3[B3.
2.7 Step 6: In-Depth Analysis
In-depth analysis was based on expert interpretation of the
evidence. Supervised by the group head and consultants
CD and JE, reviewer RJ screened the remaining 332
selected publications by reading the full text. Another 63
papers were excluded for reasons such as assessing MISGD
and xerostomia as an outcome of minor importance, leav-
ing 269 articles for in-depth analysis. Figure 1 depicts the
steps of our work process and the distribution of the
selected publications according to their score for level of
evidence.
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As a consequence of step 6, we derived three lists of
medications:
1. 56 medications with strong evidence that were quoted
in articles with scores A1 or B1.
2. 50 medications with moderate evidence that were
quoted in articles with scores A2 or B2 but not A1 or
B1.
3. 48 medications with weak evidence that were quoted
in articles with scores not higher than A3 or B3.
3 Results
3.1 Anatomical Therapeutic Chemical (ATC)
Classification of Drugs
The World Health Organization Collaborating Centre for
Drug Statistics Methodology developed the Anatomical
Therapeutic Chemical (ATC) classification system with
defined daily doses (DDDs) as a system to classify thera-
peutic drugs. This system, which we also used, divides
drugs into five different groups according to the organ or
system on which they act and their chemical, pharmaco-
logical, and therapeutic properties. The first level contains
14 main groups according to anatomical site of action, with
therapeutic subgroups (second level). The third and fourth
levels are pharmacological and chemical subgroups,
respectively, and the fifth level is the chemical compound
itself.
We found that nine of the 14 groups in the first level
contained medications reported with a strong or moderate
level of evidence to be associated with SGD, xerostomia,
or subjective sialorrhea: alimentary tract and metabolism,
cardiovascular system, genitourinary system and sex hor-
mones, anti-infectives for systemic use, anti-neoplastic and
immunomodulating agents, musculoskeletal system, ner-
vous system, respiratory system, and sensory organs.
Among the 94 subgroups under the second level, 26 con-
tain agents were reported to be associated with SGD, with
22 having strong evidence, namely drugs for functional
gastrointestinal disorders, anti-emetics and anti-nauseants,
anti-obesity preparations, anti-hypertensives, diuretics,
beta-blocking agents, calcium channel blockers, urologi-
cals, anti-neoplastic agents, muscle relaxants, drugs for the
treatment of bone diseases, analgesics, anti-epileptics, anti-
Parkinson drugs, psycholeptics, psychoanaleptics, other
nervous system drugs, anti-muscarinic drugs for obstruc-
tive airway diseases, anti-histamines for systemic use, and
ophthalmologicals. The third level is not included in
Table 1 since it would add very little information. For the
fourth level and its 882 subgroups described in the ATC/
DDD system, 64 medication classes were found to be
associated with SGD, and in 37 of these subgroups the
association of SGD with the medications had stronger
evidence. At the fifth level, 106 substances of the 4679
specified in the system were reported with a strong or
moderate level of evidence to be associated with SGD. Of
those, 56 drugs had a higher level of evidence of associa-
tion with SGD (see Table 2).
Fig. 1 Adapted PRISMA
(Preferred Reporting Items for
Systematic Reviews and Meta-
Analyses) flowchart of the
paper-selection process
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3.2 Medications with Strong Evidence
Fifty-six medications had strong evidence of interference
with salivary gland function. These medications could be
categorized into the following eight of the ten anatomical
main groups (first level in the ATC system): alimentary
tract and metabolism (A), cardiovascular system (C),
genitourinary system and sex hormones (G), anti-neoplas-
tic and immunomodulating agents (L), musculoskeletal
system (M), nervous system (N), respiratory system (R),
and sensory organs (S). More than half (36) belong to the
ATC main category of nervous system, and the most cited
in the literature are oxybutynin (21 papers), tolterodine
(19), duloxetine (19), quetiapine (14), bupropion (12),
olanzapine (11), solifenacin (11), clozapine (9), fluoxetine
(9), and venlafaxine (8). Oxybutynin, tolterodine, and
solifenacin are urologicals, while the remainder act on the
nervous system. All medications on this list except alen-
dronate, bendroflumethiazide, and clonidine have been
reported to cause xerostomia, whereas SGH has been ver-
ified (via measurement of salivary flow rate) for alen-
dronate, amitriptyline, atropine, bendroflumethiazide,
clonidine, fluoxetine, furosemide, oxybutynin, paroxetine,
propiverine, propiverine, scopolamine, sertraline, solife-
nacin, and tolterodine. Sialorrhea was found to be an
adverse effect of clozapine, olanzapine, and venlafaxine, as
objectively assessed excess salivation, and of quetiapine
and risperidone, as a symptom. Animal experiments offer
an explanation for the dual action (oral dryness and sial-
orrhea) of clozapine [63, 120]. Dysgeusia was reported
after administration of amitriptyline, bevacizumab,
buprenorphine, fluoxetine loxapine, quetiapine, and ser-
traline; dental caries were associated with chlorpromazine
and lithium; oral candidiasis was associated with olanza-
pine; and burning mouth sensation was associated with
amitriptyline (not in Table 2). The properties of the various
drugs listed in column 3 of Tables 2 and 3 were primarily
derived from the textbook Goodman and Gilman’s The
Pharmacological Basis of Therapeutics [202].
3.3 Medications with Moderate Evidence
Fifty medications had a moderate level of evidence of
effects on salivary glands. These medications belonged to
the following seven of the ten main anatomical groups (first
level according to the ATC classification system): ali-
mentary tract and metabolism, cardiovascular system,
genitourinary system and sex hormones, anti-infectives for
systemic use, nervous system, and respiratory system.
Medications under the ATC category ‘nervous system’
were also the most commonly quoted medications in
Table 3. Xerostomia is an adverse effect of all the drugs
listed in Table 3 except clobazam, whereas SGH was
reported with darifenacin and metoprolol. Enalapril,
haloperidol, and methyldopa were reported to cause a
subjective feeling of sialorrhea. Objective sialorrhea was
reported only with clobazam. Three medications (aze-
lastine, enalapril, and fluvoxamine) were reportedly asso-
ciated with dysgeusia, and one (haloperidol) was associated
with dental caries (not in Table 3).
3.4 Medications with Weak Evidence
In total, 48 medications were reported to cause a range of
adverse oral effects, such as xerostomia, SGH, sialorrhea,
burning mouth sensation, dysgeusia, and dental caries
(Table 4).
4 Discussion
Saliva plays a crucial role in maintaining the health and
functioning of the mouth. Its functions include (1) main-
taining a moist oral mucosa, (2) mucinous content acting as
a lubricant in the mouth and oesophagus, (3) taste recog-
nition by acting as a medium for suspension of tastants, (4)
digestion of starches with the help of amylase, (5) acid
buffering in the mouth and oesophagus mainly by bicar-
bonate, (6) protection of teeth from acids by being super-
saturated with respect to tooth mineral and by contributing
to the acquired enamel pellicle, (7) modulation of the oral
microbiota with the help of anti-bacterial, anti-viral, and
anti-fungal components, and (8) facilitating wound healing
in the oral cavity [272]. Medications may act on the central
nervous system and/or at the neuroglandular junction,
explaining the pathogenesis of MISDG. The secretory cells
are supplied with muscarinic M1 and M3 receptors, a1-
and b1-adrenergic receptors, and certain peptidergic
receptors that are involved in the initiation of salivary
secretion [273]. It is therefore understandable that drugs
that have antagonistic actions on the autonomic receptors
but that are used to treat dysfunctions in the various
effectors of the autonomic nervous system may also affect
the functions of salivary glands and thus cause oral dry-
ness. However, in some cases, the cause of oral dryness is
not as evident, as with the bisphosphonate alendronate that
was reported to reduce the unstimulated secretion of saliva
[13].
The anti-muscarinic drugs are well-known inducers of
oral dryness as they prevent parasympathetic (cholinergic)
innervation from activating the secretory cells. Surpris-
ingly, clinical studies directly focusing on the secretion of
saliva and the flagship of the anti-muscarinics, atropine,
seem few. This is in contrast to numerous studies on ani-
mals, starting with the observations of the pioneers of
salivary physiology in the 1870s.
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Table 1 Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with higher and moderate level of evidence,
grouped according to their inclusion in first, second, fourth, and fifth ACT levels
First level, anatomical main
group
Second level, therapeutic
subgroup
Fourth level, chemical subgroup Fifth level, chemical
substance
ATC code
Alimentary tract and
metabolism
Drug for functional GI
disorder
Synthetic anti-cholinergics, quaternary
ammonium compounds
Propantheline A03AB05
Belladonna alkaloids, tertiary amines Atropine A03BA01
Hyoscyamine A03BA03
Belladonna alkaloids, semisynthetic,
quaternary ammonium compounds
Scopolamine/
hyoscine
A03BB01
Anti-emetics and anti-
nauseants
Other anti-emetics Scopolamine/
hyoscine
A04AD01
Anti-obesity preparations,
excl. diet products
Centrally acting anti-obesity products Phentermine A08AA01
Dexfenfluramine A08AA04
Sibutramine A08AA10
Peripherally acting anti-obesity products Orlistat A08AB01
Serotonin–noradrenaline–dopamine
reuptake inhibitor
Tesofensine ND
Cardiovascular system Cardiac therapy Anti-arrhythmics, class Ib Mexiletine C01BB02
Anti-hypertensives Methyldopa Methyldopa C02AB01
Imidazoline receptor agonists Clonidine C02AC01
Diuretics Thiazides, plain Bendroflumethiazide C03AA01
Sulfonamides, plain Furosemide C03CA01
Vasopressin antagonists Tolvaptan C03XA01
Beta-blocking agents Beta-blocking agents, non-selective Timolol C07AA06
Beta-blocking agents, selective Metoprolol C07AB02
Atenolol C07AB03
Calcium channel blockers Dihydropyridine derivatives Isradipine C08CA03
Phenylalkylamine derivatives Verapamil C08DA01
Agents acting on the renin-
angiotensin system
ACE inhibitors, plain Enalapril C09AA02
Lisinopril C09AA03
Genitourinary system and
sex hormones
Urologicals Drugs for urinary frequency and
incontinence
Oxybutynin G04BD04
Propiverine G04BD06
Tolterodine G04BD07
Solifenacin G04BD08
Trospium G04BD09
Darifenacin G04BD10
Fesoterodine G04BD11
Imidafenacin ND
Alpha-adrenoreceptor antagonists Alfuzosin G04CA01
Terazosin G04CA03
Anti-infectives for systemic
use
Anti-virals for systemic use Protease inhibitors Saquinavir J05AE01
Nucleoside and nucleotide reverse
transcriptase inhibitors
Didanosine J05AF02
Lamivudine J05AF05
Non-nucleoside reverse transcriptase
inhibitors
Nevirapine J05AG01
Etravirine J05AG04
Other anti-virals Raltegravir J05AX08
Maraviroc J05AX09
Anti-neoplastic and
immunomodulating
agents
Anti-neoplastic agents Monoclonal antibodies Bevacizumab L01XC07
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Table 1 continued
First level, anatomical main
group
Second level, therapeutic
subgroup
Fourth level, chemical subgroup Fifth level, chemical
substance
ATC code
Musculoskeletal system Muscle relaxants Other centrally acting agents Baclofen M03BX01
Tizanidine M03BX02
Cyclobenzaprine M03BX08
Drugs for treatment of
bone diseases
Bisphosphonates Alendronate M05BA04
Nervous system Anesthetics Opioid anesthetics Fentanyl N01AH01
Analgesics Natural opium alkaloids Morphine N02AA01
Dihydrocodeine N02AA08
Phenylpiperidine derivatives Fentanyl N02AB03
Oripavine derivatives Buprenorphine N02AE01
Morphinan derivatives Butorphanol N02AF01
Other opioids Tramadol N02AX02
Tapentadol N02AX06
Other anti-migraine preparations Clonidine N02CX02
Anti-epileptics Fatty acid derivatives Sodium
valproate/valproic
acid
N03AG01
Other anti-epileptics Gabapentin N03AX12
Pregabalin N03AX16
Anti-Parkinson drugs Dopamine agonists Rotigotine N04BC09
Psycholeptics Phenothiazines with aliphatic side-chain Chlorpromazine N05AA01
Phenothiazines with piperazine structure Perphenazine N05AB03
Butyrophenone derivatives Haloperidol N05AD01
Indole derivatives Sertindole N05AE03
Ziprasidone N05AE04
Lurasidone N05AE05
Diazepines, oxazepines, thiazepines, and
oxepines
Loxapine N05AH01
Clozapine N05AH02
Olanzapine N05AH03
Quetiapine N05AH04
Asenapine N05AH05
Benzamides Amisulpride N05AL05
Lithium Lithium N05AN01
Other anti-psychotics Risperidone N05AX08
Aripiprazole N05AX12
Paliperidone N05AX13
Benzodiazepine derivatives (anxiolytics) Clobazam N05BA09
Benzodiazepine-related drugs Zolpidem N05CF02
Eszopiclone N05CF04
Zopiclone N05CF01
Other hypnotics and sedatives Scopolamine/
hyoscine
N05CM05
Dexmedetomidine N05CM18
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The number of patients adversely affected by a specific
drug, as well as the severity of the effect of this drug, are
usually dose dependent. Figures for these parameters are
not presented in the current study. Lack of saliva is often
manifested as the sensation of dry mouth (xerostomia). A
number of studies have suggested an association between
the incidence of xerostomia and the number and dose of
medications [274]. That study also discussed secondary
effects of MISGD in promoting caries or oral mucosal
alterations.
Management of MISGD has mainly been based on a
trial-and-error approach. Use of intraoral topical agents,
such as a spray containing malic acid, sugar-free chewing
gums or candy, saliva substitutes, or non-alcoholic
mouthwashes to moisten or lubricate the mouth have
served as the mainstay of treatment for patients with a dry
Table 1 continued
First level, anatomical main
group
Second level, therapeutic
subgroup
Fourth level, chemical subgroup Fifth level, chemical
substance
ATC code
Psychoanaleptics Non-selective monoamine reuptake
inhibitors
Desipramine N06AA01
Imipramine N06AA02
Amitriptyline N06AA09
Nortriptyline N06AA10
Doxepin N06AA12
Dosulepin N06AA16
Selective serotonin reuptake inhibitors Fluoxetine N06AB03
Citalopram N06AB04
Paroxetine N06AB05
Sertraline N06AB06
Escitalopram N06AB10
Other anti-depressants Bupropion N06AX12
Venlafaxine N06AX16
Reboxetine N06AX18
Duloxetine N06AX21
Desvenlafaxine N06AX23
Vortioxetine N06AX26
Centrally acting sympathomimetics Methylphenidate N06BA04
Dexmethylphenidate N06BA11
Lisdexamfetamine N06BA12
Other nervous system
drugs
Drugs used in nicotine dependence Nicotine N07BA01
Drugs used in alcohol dependence Naltrexone N07BB04
Drugs used in opioid dependence Buprenorphine N07BC01
ND ND Dimebon ND
Tesofensine ND
Respiratory system Nasal preparations Anti-allergic agents, excl. corticosteroids Azelastine R01AC03
Drugs for obstructive
airway diseases
Anti-cholinergics Tiotropium R03BB04
Anti-histamines for
systemic use
Aminoalkyl ethers Doxylamine R06AA09
Piperazine derivatives Cetirizine R06AE07
Levocetirizine R06AE09
Other anti-histamines for systemic use Ebastine R06AX22
Desloratadine R06AX27
Sensory organs Ophthalmologicals Sympathomimetics in glaucoma therapy Brimonidine S01EA05
Anti-cholinergics Atropine S01FA01
Other anti-allergics Azelastine S01GX07
ACE angiotensin-converting enzyme, ATC Anatomical Therapeutic Chemical, GI gastrointestinal, ND not determined
a Bold type indicates higher level of evidence
A. Wolff et al.
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mouth. Parasympathomimetic agents with potent mus-
carinic-stimulating properties, such as pilocarpine and
cevimeline, and anti-cholinesterases, which reduce the rate
of acetylcholine metabolism, have been used as systemic
sialogogues. Although they increase salivation signifi-
cantly, the adverse effect profile of these drugs upon sys-
temic administration restricts their use in patients with
MISGD. A local application of these categories of drugs
onto the oral epithelium, with the aim of activating the
underlying minor glands, may be an alternative approach.
It is also necessary to ensure salivary gland functionality
before administering these medications. Newer manage-
ment methods include electrostimulation. Other manage-
ment options for MISGD include possibly reducing the
number of medications or the dosage or replacing them
with medications or formulations with fewer xerogenic
effects. Little evidence is available on this important topic;
however, when dental treatment is needed, close commu-
nication between the dentist (who has to deal with the
adverse effects) and the prescribing physician is warranted
to obtain the best outcome for the patient [275].
The present paper tries to fill the lacunae in regard to
evidence-based listing of the effects of medications on
salivary function as found in the current scientific litera-
ture. We conducted an extensive search of the literature
related to MISGD, followed by meticulous scrutiny and
analysis of the articles. However, it is still possible that a
few medications were missed, and the lists in Tables 2 and
3 may not be exhaustive. Grading the evidence and rele-
vance of each scientific article was a major issue. Conse-
quently, the number of medications with strong or
moderate evidence of being associated with SGD and
xerostomia in our lists is much smaller than in other lists
[1–6, 9]. Moreover, some studies may have recorded
salivary disorders only in an adverse effect table, and these
would have been missed by our search. An additional issue
is that our study does not include preparations containing
more than one agent. However, any medication included in
a mixed medication in these lists may have the potential to
influence the salivary effects of the overall preparation. A
further matter that warrants consideration is the possibility
that certain drugs, while not exerting xerogenic effect
when taken individually (and therefore not appearing in
these lists), may do so as a result of drug–drug interaction
if consumed together in a polypharmacy context [7, 8]. It
should also be noted that, for some medications not
included in this review because peer-reviewed publications
on their salivary side effects were lacking, such side effects
could have been mentioned on their monographs according
to their manufacturer’s controlled clinical trial. Finally,
this article does not report the potency and frequency of
salivary effects of the medications, as these data were
rarely available.T
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The study suggests that medications acting on almost all
systems of the body may also cause side effects related to
the salivary system. At higher levels of the classification
tree, the analysis seems to yield more specific details of the
medications and their modes of action leading to SGD and
xerostomia. Hence, the selection of an alternate drug with a
similar effect on the desired system but fewer adverse
salivary effects may be attempted based on this list.
However, the possibility exists that other drugs that belong
to the same level, especially at the fourth level of the ATC/
DDD classification, may have a similar effect on salivary
glands as the drug to be replaced.
Very few studies used objective measurements of sali-
vary flow rates in the context of a medication adverse
effect [7, 8, 13, 48]. Further, few articles seem to have
correlated the results of such objective measurements with
the subjective feelings of the patients receiving these
drugs. Though animal studies have established a reduced
salivary flow rate as an effect of medications, the subjec-
tive feeling of dryness (xerostomia) obviously cannot be
registered in animals; hence, the relationship between
changes in salivary flow rate and subjective feelings of
dryness/drooling has been ambiguous
[104, 120, 138–140, 148].
It has been reported that xerostomia in healthy subjects
is not experienced until the unstimulated flow rate of whole
saliva has been reduced to 40–50% of normal [27]. Fur-
thermore, whether changes in the composition of the sali-
vary secretion can also affect the subjective feelings of the
patient remains to be clarified. However, the main diffi-
culty encountered was the rarity of studies in which sali-
vary flow rate or composition was actually measured
before and after patients were prescribed medication.
Moreover, baseline data were available for virtually no
patients regarding their unstimulated saliva flow rates
before they require medications. It seems to be only in
Sweden that dental students are taught to measure the
salivary flow rates of their patients to provide baseline
values for any subsequent salivary problems that may
develop. We suggest this is a valuable approach that should
also be introduced in other countries.
Medications were also reported to cause other oral
adverse effects. Aliko et al. [274] point out that although
independent reports relate a burning sensation of the oral
mucosa and/or dysgeusia with MISGD, the relationship has
not been established objectively. A few articles (albeit of
moderate or weak level of evidence) mention that can-
didiasis and dental caries are associated with the use of
certain drugs. None of these studies has tested the rela-
tionship between the pharmacokinetics of the drug, its
effect on salivary glands, and other oral adverse effects
reported [274]. Dawes et al. [272] reported that con-
stituents of saliva have anti-fungal, anti-viral, and anti-T
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Table 4 Medications reported to induce xerostomia, salivary gland hypofunction, or sialorrhea with weaker level of evidence
Drug name Number of citations for: Sources per level of evidence (n) Total publications (n) References
Oral ‘dryness’ Sialorrhea
Xerostomia SGH Subjective Objective A3 B3
Amiloride 0 1 0 0 1 0 1 [14]
Apraclonidine 1 0 0 0 0 1 1 [26]
Asimadoline 1 0 0 0 0 1 1 [252]
Atomoxetine 1 0 0 0 0 1 1 [253]
Biperiden 1 1 0 0 1 0 1 [14]
Chlorpheniramine 1 0 0 0 0 1 1 [254]
Chlorprothixene 0 1 0 0 1 0 1 [14]
Cisplatin 1 0 0 0 0 1 1 [255]
Clomipramine 3 0 0 0 0 3 3 [90, 95, 145]
Cyclothiazide 0 1 0 0 1 0 1 [14]
Cytisine 1 0 0 0 0 1 1 [256]
Diltiazem 0 1 0 0 1 0 1 [14]
Dimenhydrinate 2 0 0 0 0 2 2 [167, 254]
Diphenhydramine 1 0 0 0 0 1 1 [254]
Disopyramide 1 0 0 0 1 0 1 [14]
Flupirtine 1 0 0 0 0 1 1 [257]
Granisetron 1 0 0 0 0 1 1 [258]
Guanfacine 2 0 0 0 0 2 2 [53, 259]
Interleukin-2a 0 1 0 0 1 0 1 [14]
Ipratropium 1 0 0 0 0 1 1 [260]
Levomepromazine 0 1 0 0 1 0 1 [14]
Maprotiline 1 1 0 0 1 0 1 [14]
Mazindol 1 0 0 0 0 1 1 [100]
Melperone 0 1 0 0 1 0 1 [14]
Mepyramine 1 0 0 0 0 1 1 [254]
Metiamide 0 1 0 0 1 0 1 [14]
Milnacipran 3 0 0 0 0 3 3 [85, 261, 262]
Mirtazapine 2 0 0 0 0 2 2 [18, 263]
Moclobemide 1 0 0 0 0 1 1 [112]
Modafinil 2 0 0 0 0 2 2 [90, 264]
Mosapride 1 0 0 0 0 1 1 [265]
Moxifloxacin 1 0 0 0 0 1 1 [266]
Moxonidine 3 0 0 0 0 3 3 [50, 53, 267]
Nefazodone 2 0 0 0 0 2 2 [268, 269]
Oxitropium 1 0 0 0 0 1 1 [260]
Perindopril 1 0 0 0 0 1 1 [270]
Pethidine 0 1 0 0 1 0 1 [14]
Phenelzine 1 0 0 0 0 1 1 [113]
Pheniramine 0 1 0 0 0 1 1 [254]
Promazine 1 0 0 0 0 1 1 [157]
Protriptyline 2 0 0 0 0 2 2 [90, 100]
Pseudoephedrine 1 0 0 0 0 1 1 [207]
Rilmenidine 2 0 0 0 0 2 2 [53, 266]
Selegiline 1 1 0 0 1 1 2 [14, 112]
Thioridazine 2 1 0 0 1 0 1 [14]
Tianeptine 1 0 0 0 1 0 1 [271]
Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia and Subjective Sialorrhea
bacterial properties, which indicates the role of saliva in
controlling the oral microbiota and correlates SGH with
occurrence of oral candidiasis. The relationship between
SGH, dental caries, and oral candidiasis is well known and
established. However, the same has not been tested in the
context of MISGD in the current literature.
The present paper may help clinicians and researchers
consider whether the medications they prescribe or inves-
tigate may lead to SGD or xerostomia. A few scenarios
follow:
(a) A clinician needs to evaluate which drugs from the
medication list of his/her patient have potential
adverse salivary effects. The clinician may take the
following steps:
(i) Search in Tables 2 and 3 for the medications by
alphabetical order.
(ii) If the medications are not found, there is
probably no published evidence for a salivary
adverse effect.
(iii) If found and they wish to know more about the
medication type, they can search Table 1 using
the ATC code(s) found in column 2 of Tables 2
and 3. These codes are in the last column of
Table 1 in alphabetical and numerical order.
(b) Before prescribing a medication, a clinician wishes to
assess its potential salivary adverse effects. The above
decision tree is also recommended in this situation.
(c) A treated patient complains of salivary symptoms but
the clinician cannot find any of the medications in
Tables 2 or Table 3. However, it is plausible that
additional medications not included in these
tables could also affect salivary glands if they belong
to the same ATC category at any level. For example,
the anti-obesity medications fenfluramine, amfepra-
mone, mazindol, etilamfetamine, cathine, cloben-
zorex, mefenorex, and lorcaserin are all ‘centrally
acting anti-obesity products’, ATC A08AA [276], and
may act similarly to dexfenfluramine, which belongs
to the same category and appears in Table 3. Such an
association may provide an explanation for the
patient’s symptoms.
(d) A clinician needs to prescribe medication to a patient
with Sjo¨gren’s syndrome or who has undergone
radiotherapy to the head and neck area and wishes
to avoid worsening the patient’s xerostomia. If, for
example, the required drug is a muscle relaxant, the
clinician may search the ATC website [277] under
‘muscle relaxants’ and then double check the sub-
groups and Table 1. There, they will find that ‘other
centrally acting agents’ may have salivary effects and
thus choose a medication belonging to any of the
other subgroups.
(e) A researcher wishes to know whether a certain type of
medication has salivary effects and at what level of
evidence.
(i) The researcher may start searching Table 1 for
the type of medication according to the anatom-
ical site of action (first level), therapeutic effect
(second level), chemical characteristic (fourth
level), or generic name (fifth level).
(ii) If no relevant category is found, there is
probably no published evidence for adverse
salivary effects of this drug type.
(iii) If the drug type is found at any of the levels in
bold text, one of the drugs at the fifth level
belonging to the category may be searched for
in Table 2, where the medications are in
alphabetical order and information is available,
i.e., type and number of publications and
references.
(iv) If the drug type is found but not in bold text, the
researcher may proceed as in (iii) above but in
Table 3 instead of Table 2.
5 Conclusions
Most investigators relied on the subjective opinion of the
individuals or patients about whether they had too little or
an excessive secretion of saliva. Thus, we conclude that
further RCTs that include saliva collection are warranted
for the assessment of potential salivary effects of many
Table 4 continued
Drug name Number of citations for: Sources per level of evidence (n) Total publications (n) References
Oral ‘dryness’ Sialorrhea
Xerostomia SGH Subjective Objective A3 B3
Triprolidine 1 0 0 0 0 1 1 [254]
Zimelidine 0 1 0 0 1 0 1 [14]
SGH salivary gland hypofunction
A. Wolff et al.
medications. Unstimulated and stimulated salivary flow
rates should be measured before and at intervals after
starting the drug. In addition, a record of changes in the
patients’ subjective feelings over time should also be kept.
Ideally, studies should also aim to assess changes in sali-
vary composition, since these may also relate to SGD.
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